Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study

Journal of Pain and Symptom Management

Volumn 12, Issue 4, 1996, Pages 234-240

  Hammack, Julie E ^a   Mailliard, James A ^b   Loprinzi, Charles L ^a   Respond, Raylene M ^b   O'Fallon, Judith R ^a   Wilwerding, Mary B ^b   Reuter, Nicholas F ^c   Michalak, John C ^d   Fidler, Pat ^b   Miser, Angela W ^a  

^a MAYO CLINIC   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c St Cloud Clin of Internal Medicine   (United States)

^d Siouxland Hematology Oncology Associates   (United States)

Author keywords

cancer pain; opioids; Transdermal fentanyl

Indexed keywords

FENTANYL DERIVATIVE;

ADULT; AGED; AMBULATORY CARE; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; RESPIRATION DEPRESSION; SEDATION; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT PLANNING;

EID: 0030271489     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/0885-3924(96)00191-1     Document Type: Article

References (19)

1. 1. Janssen PAJ. A review of the chemical features associated with strong morphine-like activity. Br J Anaesth 1962;34:260.
2. 2. Bailey PL, Stanley TH. Narcotic intravenous anesthetics. In: Miller RD, ed. Anesthesia. New York: Churchill Livingstone, 1990:281-366.
3. 3. Wester RC, Maibach HI. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab Rev 1983;14:169-205.
4. 4. Gourlay GK, Kowalski SR, Plummer JL, et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 1990; 40:21-28.
5. 5. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1992;70:928-934.
6. 6. Lehmann KA, Zech D. Transdermal fentanyl: clinical pharmacology. J Pain Symptom Manage 1992;7(suppl 3):S8-S16.
7. 7. Plezia PM, Linford J, Kramer TH, et al. Transdermal therapeutic system (fentanyl) for postoperative pain: an efficacy, toxicity, and pharmacokinetic trial. Anesthesiology 1986;65:A210.
8. 8. Holley FO, Van Steennis C. Transdermal administration of fentanyl for postoperative analgesia. Anesthesiology 1986;65:A548.
9. 9. Caplan RA, Ready LB, Olsson GL, et al. Transdermal delivery of fentanyl for postoperative pain control. Anesthesiology 1986;65:A196.
10. 10. Nimmo WS, Duthie DJR. Plasma fentanyl concentrations after transdermal or IV infusion of fentanyl. Anesthesiology 1986;65:A559.
11. 11. Simmons MA, Payne R, Richenbacher J, et al. TTS (fentanyl) in the management of pain in patients with cancer. Proc Am Soc Clin Oncology 1989;8:234.
12. 12. Slover R. Transdermal fentanyl: clinical trial at the University of Colorado Health Sciences Center. J Pain Symptom Manage 1992;7(suppl 3):S45-S47.
13. 13. Maves TJ, Barcellos WA. Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa. J. Pain Symptom Manage 1992; 7(suppl 3):S58-S62.
14. 14. Miser AW, Narang PK, Dothage JA, et al. Transdermal fentanyl for pain control in patients with cancer. Pain 1992;37:15-21.
15. 15. Zech D, Grond S, Lynch J, et al. Transdermal fentanyl and initial dose-finding with patients-controlled analgesia in cancer pain. Pain 1992;50:293-302.
16. 16. Portenoy RK. Cancer pain: epidemiology and syndromes. Cancer 1989;63:2298-2307.
17. 17. Payne R. Cancer pain: anatomy, physiology, and pharmacology. Cancer 1989;63:2266-2274.
18. 18. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-2662.
19. 19. Ahmedzai S, Allan E, Fallon M, et al. Transdermal fentanyl in cancer pain. J Drug Dev 1994;6:93-97.